Greater Reach Model Launched by Greater Than One in November
Advanced media marketing and technology company, Greater Than One, launched the Greater Reach model (GRM), a proprietary data tool designed to pinpoint the perfect channel mix, frequency, and budget allocation to reach target audiences with laser focus and maximum ROI. The model—which provides comprehensive data analysis and delivers precise and actionable recommendations—ensures that a client’s marketing goals and target audiences are reached. The model leverages nearly 25 years of data and health industry marketing experience, enabling the agency to predict and achieve measurable improvements in a client’s marketing performance.
Greater Than One’s nonprofit subsidiary wins Google Grant.
“The world of technology is evolving every day,” said Amanda PowersHan, Chief Media & Marketing Officer of Greater Than One. “Our model analyzes performance data and industry trends to identify the most effective channels for reach and engagement. We built Greater Reach to ensure that our clients’ marketing budgets are allocated in the most efficient manner possible, which allows them the highest ROI.”
ProVate for Women With Pelvic Organ Prolapse Announced by ConTIPI Medical & EVERSANA
ConTIPI Medical—an innovator in providing non-surgical and disposable solutions for women with various pelvic floor dysfunctions, and EVERSANA—a leading provider of global commercial services to the life sciences industry, today announced the U.S. commercial launch of ProVate to help women experiencing pelvic organ prolapse (POP). ProVate—a ready-to-use, disposable device for patients’ at- home use—is now available for physicians across the U.S. to prescribe. It is inserted vaginally in small dimensions within a disposable applicator, very similar to the concept of the menstrual tampon applicator, empowering women to take control of their medical condition.
ConTIPI Medical & EVERSANA announces non-surgical medical device, ProVate, for
women Pelvic Organ Prolapse.
“Today marks a significant milestone in women’s health in the United States as we are thrilled to see that ProVate is now available for physicians to prescribe for patients with pelvic organ prolapse,” said Dr. Elan Ziv, MD, OBGYN, Urogynecologist, CEO & Medical Director with ConTIPI Medical. “EVERSANA has been a tremendous partner throughout the commercialization process, and we look forward to continued work with their best-in-class team.”
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U SubStudy of Vepdegestrant in Combination with Abemaciclib at Breast Cancer Symposium
Data will be presented in a poster at the 2024 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas by Arvinas, Inc. and Pfizer, Inc. The preliminary data is from the ongoing Phase 1b portion of the TACTIVE-U sub-study of vepdegestrant, in combination with abemaciclib, among patients with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
Preliminary results from 16 patients in the Phase 1b sub-study demonstrated a tolerable safety profile for the combination of abemaciclib 150mg twice daily (BID), with the recommended Phase 3 monotherapy dose of vepdegestrant (200mg once daily; QD). An encouraging clinical benefit rate of 62.5% was observed among patients with both mutant ESR1 and wild-type ESR1 disease who had all been previously treated with a CDK4/6 inhibitor. Pharmacokinetic data demonstrated no significant drug-drug interaction between vepdegestrant and abemaciclib, and no clinically meaningful effect on abemaciclib exposure was observed.
“The preliminary results from this Phase 1b sub-study in patients whose cancer had previously progressed after receiving a CDK4/6 inhibitor are encouraging,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer at Arvinas. “These data further reinforce our belief that vepdegestrant can be used in multiple combination regimens across the metastatic breast cancer setting, and has the potential to become a bestin-class backbone ER therapy. We are pleased to continue in the Phase 2 portion of the study evaluating the standard starting dose of abemaciclib in combination with vepdegestrant.”
Completion of Enrollment by Lisata Therapeutics in the CENDIFOX Trial
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”)—a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases—today announced the successful completion of patient enrollment in all three cohorts of the Phase 1b/2a CENDIFOX trial. This investigator-initiated trial is evaluating the safety and efficacy of Lisata’s iRGD cyclic peptide product candidate—certepetide—in combination with FOLFIRINOXbased therapies for pancreatic, colon, and appendiceal cancers. The openlabel CENDIFOX trial is designed to assess the safety and therapeutic effects of combining certepetide with neoadjuvant FOLFIRINOX regimens, with or without panitumumab, across pancreatic, colon, and appendiceal cancers. The study, conducted solely at The University of Kansas Cancer Center, enrolled a total of 66 patients: 35 resectable and borderline resectable pancreatic cancer patients, 18 highgrade colon and appendiceal cancer patients with peritoneal metastasis, and 13 colon cancer patients with oligo-metastatic disease.
“The successful enrollment of all three cohorts in the CENDIFOX trial is another significant milestone, bringing us closer to validating certepetide’s potential as a transformative treatment for advanced solid tumors,” stated Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Lisata. “By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm. We are excited about the progress of the CENDIFOX trial and eagerly anticipate reporting the results from this important study in 2025.”
Liver Signals Halt BioAge’s Obesity Study in Post-IPO Setback
BioAge Labs announced it is discontinuing the Phase II STRIDES trial evaluating azelaprag, dealing a blow to the company’s obesity drug development efforts and triggering a nearly 70% stock price collapse. STRIDES was designed to evaluate azelaprag, as both a monotherapy and in combination with Eli Lilly’s dual GIP/GLP-1 receptor agonist Zepbound (tirzepatide). The study aimed to enroll approximately 220 obese individuals aged 55 and older, focusing on body weight reduction and other outcomes like safety and tolerability.
BioAge Labs discontinues weight loss
drug that’s linked to liver transaminitis.
“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm.”
BioAge said it discovered liver transaminitis without clinically significant symptoms in 11 patients in the azelaprag treatment groups out of 204 subjects enrolled to date. However, they will continue clinical follow-up with enrolled subjects and intend to share updated plans for the azelaprag program in the first quarter of 2025.
“Patient safety is our top priority in the conduct of our clinical studies,” said CEO Kristen Fortney. “We made the difficult decision…because it became clear that the emerging safety profile of the current doses tested is not consistent with our goal of a bestin-class oral obesity therapy.”
